GNMX - Aevi Genomic Medicine, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.1850
-0.0088 (-4.54%)
As of 11:17AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1938
Open0.1900
Bid0.1850 x 800
Ask0.1898 x 900
Day's Range0.1812 - 0.1950
52 Week Range0.1500 - 1.4000
Volume271,563
Avg. Volume1,295,214
Market Cap11.982M
Beta (3Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 months ago

    GNMX: ASCEND Misses Primary Endpoint: GNMX indicates they are not giving up in AEVI-001

    On January 2nd Aevi (GNMX) announced that ASCEND, the phase II trial evaluating their non-stimulant glutamatergic neuromodulator in pediatric and adolescent subjects with ADHD, failed to meet its primary endpoint of a statistically significant reduction of ADHD-RS at 6 weeks in either Part A (mGluR+ subjects) or Part B (mutation free subjects). As we have consistently stated in our coverage, given the largely positive results of SAGA and enrichment of ASCEND with only patients with mutations to nine select genes in the mGluR network, along with a pediatric weighting, we had expected ASCEND would prove successful. As a reminder about SAGA’s results (see link to our report), it did meet statistical significance on the CGI-I secondary endpoint as well as on the ADHD-RS responder measure (prespecified as decrease of ADHD-RS score of 30% or more, which is considered a clinical response).

  • Benzinga6 months ago

    The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

    Bristol-Myers Squibb Co (NYSE: BMY) announced a deal to buy Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction with an equity value of approximately $74 billion. Separately, the company announced FDA approval for an expanded indication for its Sprycel tablets to include the treatment of pediatric patients one year of age and older, with newly diagnosed Philadelphia chromosome-positive, or Ph+, acute lymphoblastic leukemia in combination with chemotherapy.

  • Zacks Small Cap Research8 months ago

    GNMX: With ASCEND Enrollment Completed, Read-Out Expected In Q1’19

    Aevi Genomic Medicine (GNMX) reported Q3 financial results and provided a business update. Just two months later, GNMX announced that part ‘B’ (i.e. Also noteworthy is that while the initial plan was for parts A and B to enroll and read-out sequentially, given the rapid enrollment of part B, the expectation is now that top-line data will be announced for both in January.

  • Associated Press9 months ago

    Aevi Genomic Medicine: 3Q Earnings Snapshot

    On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 12 cents. The company's shares closed at $1.09. A year ago, they were trading at $1.66. _____ This story was generated ...

  • Zacks Small Cap Research11 months ago

    GNMX: AEVI Q2 Update: ASCEND Data By Year-End, Enhanced 001 Co-Crystal

    Despite the slight additional delay to ASCEND (as a result of the optioned increased enrollment), we continue to think there may be several pipeline-related events over the very near term that could potentially favorably influence equity valuation and related pricing of any near-term financings. GNMX hopes to swap out AEVI-001 (which is in phase 2 mGlur+ ADHD ASCEND study) with an improved version. AEVI-004 provides the benefits of intellectual property protection (out to 2039) and is designed to maintain substantially similar solubility, dissolution and pharmakokinetics of AEVI-001 but with (per GNMX's press release) "greater stability and a higher melting point".

  • Associated Presslast year

    Aevi Genomic Medicine: 2Q Earnings Snapshot

    On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 14 cents. The company's shares closed at $1.10. A year ago, they were trading at $1.20. _____ This story was generated ...